Published in Women's Health Weekly, November 29th, 2001
The presentation was the first opportunity for AltaRex to present to the collective European oncology community its findings on the relevance of circulating levels of the tumor associated antigen CA125 both as an indicator of impending progression of ovarian cancer and as a target for OvaRex MAb.
The selection of OvaRex MAb for the special session at ECCO 11 recognizes an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly